Chronic Refractory Gout
Stage (next event)
Catalyst Info & Data Links
TITLE: SEL-212 in Chronic Refractory Gout
ClinicalTrial.gov (NCT04596540): A Study of SEL-212 in Patients With Gout Refractory to Conventional Therapy II (DISSOLVE II)
ClinicalTrial.gov (NCT04513366): A Study of SEL-212 in Patients With Gout Refractory to Conventional Therapy (DISSOLVE I)
WHAT IS THE NEXT CATALYST EVENT?
Phase 3 Data
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
Mechanism of Action
MECHANISM OF ACTION / RATIONALE
SEL-212 is a novel combination product candidate designed to sustain control of serum uric acid (SUA) levels in patients with chronic refractory gout, potentially reducing harmful tissue urate deposits which when left untreated can lead to debilitating gout flares and joint deformity. SEL-212 consists of pegadricase, Selecta’s proprietary pegylated uricase, co-administered with ImmTOR, designed to mitigate the formation of anti-drug antibodies (ADAs). ADAs develop due to unwanted immune responses to biologic medicines, rendering these therapies less potent, which remains an issue across multiple therapeutic modalities and disease states including chronic refractory gout.
Affecting approximately 160,000 people in the United States, chronic refractory gout is a painful and severe form of inflammatory arthritis that can lead to bone erosions and joint deformities resulting in loss of function and disability (Learn more HERE).
Updated by HC
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See what the community is saying - click to see full post